Anti-human CD99 antibody exerts potent antitumor effects in mantle cell lymphoma.

Cancer Immunology, Immunotherapy : CII
Nuchjira TakheawSeiji Okada

Abstract

CD99 is a surface molecule expressed on various cell types including cancer cells. Expression of CD99 on multiple myeloma is associated with CCND1-IGH fusion/t(11;14). This translocation has been reported to be a genetic hallmark of mantle cell lymphoma (MCL). MCL is characterized by overexpression of cyclin D1 and high tumor proliferation. In this study, high expression of CD99 on MCL cell lines was confirmed. Our generated anti-CD99 monoclonal antibody (mAb), termed MT99/3, exerted potent antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activities against mantle B-cell lymphoma without direct cytotoxic effects. The anti-tumor activities of mAb MT99/3 were more effective in MCL than in other B-cell lymphomas. Moreover, in a mouse xenograft model using Z138 MCL cell line, treatment of mAb MT99/3 reduced tumor development and growth. Our study indicated that mAb MT99/3 is a promising immunotherapeutic candidate for mantle cell lymphoma therapy.

References

Aug 1, 1989·European Journal of Immunology·F AubritA Bernard
Jan 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·H W SohnS H Park
Apr 6, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·R D PettersenS O Lie
Jan 29, 2002·Nature Immunology·Alan R SchenkelWilliam A Muller
Oct 9, 2002·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Isabelle AlbertiAlain Bernard
Apr 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rajat BannerjiJohn C Byrd
Dec 6, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Katia ScotlandiPiero Picci
Jan 20, 2006·Molecular Biology of the Cell·Maria Cristina ManaraKatia Scotlandi
Nov 3, 2009·Haematologica·Stefano A Pileri, Brunangelo Falini
May 11, 2010·Journal of Leukocyte Biology·Zvenyslava HusakMichael N Dworzak
Jan 5, 2011·Acta Haematologica·Sang Pyo LeeYoung Hyeh Ko
Oct 25, 2011·International Journal of Cancer. Journal International Du Cancer·Xueping HuangTong Zhao
Jul 1, 2014·British Journal of Haematology·Yiming ChenJorge Romaguera
Aug 15, 2014·Current Topics in Microbiology and Immunology·Jantine E Bakema, Marjolein van Egmond
Apr 29, 2015·Molecular Immunology·J M RedmanL M Weiner
Jun 24, 2015·The Journal of Experimental Medicine·Richard L WatsonWilliam A Muller
Aug 6, 2016·Therapeutic Advances in Hematology·Mili AroraJoseph Tuscano
Jan 27, 2017·Science Translational Medicine·Stephen S ChungChristopher Y Park
Apr 1, 2017·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Hyewon LeeYoung-Joo Won
Oct 28, 2017·Nature Reviews. Cancer·Nicolas GengenbacherHellmut G Augustin
Dec 30, 2017·Journal of Molecular Biomarkers & Diagnosis·Muthu Dhandapani, Aaron Goldman
Jan 7, 2018·Journal of Cell Communication and Signaling·Michela PaselloKatia Scotlandi
Mar 14, 2018·Genes·Maria Cristina ManaraKatia Scotlandi
Nov 7, 2018·Cellular Immunology·Witida LaopajonWatchara Kasinrerk
Apr 26, 2019·Annals of Translational Medicine·Cristiana Lo NigroMarco Carlo Merlano

❮ Previous
Next ❯

Citations

Mar 28, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Sepideh MirzaeiMasoud Najafi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody-Dependent Cell Cytotoxicity

Antibody-dependent cellular toxicity refers to the lysis of a target cell by a non-sensitized effector cell of the immune system as a result of antibodies binding to the target cell membrane and engaging the Fc receptors on the immune effector cells. Find the latest research on antibody-dependent cellular toxicity here.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.